PL357719A1 - Drugs for complications of diabetes and neuropathy and utilization thereof - Google Patents

Drugs for complications of diabetes and neuropathy and utilization thereof

Info

Publication number
PL357719A1
PL357719A1 PL01357719A PL35771901A PL357719A1 PL 357719 A1 PL357719 A1 PL 357719A1 PL 01357719 A PL01357719 A PL 01357719A PL 35771901 A PL35771901 A PL 35771901A PL 357719 A1 PL357719 A1 PL 357719A1
Authority
PL
Poland
Prior art keywords
neuropathy
complications
diabetes
drugs
utilization
Prior art date
Application number
PL01357719A
Other languages
English (en)
Polish (pl)
Inventor
Yoshiro Kitahara
Kyoko Miura
Original Assignee
Ajinomoto Co, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co, Inc. filed Critical Ajinomoto Co, Inc.
Publication of PL357719A1 publication Critical patent/PL357719A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL01357719A 2000-03-17 2001-03-15 Drugs for complications of diabetes and neuropathy and utilization thereof PL357719A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000076542 2000-03-17
PCT/JP2001/002094 WO2001068136A1 (fr) 2000-03-17 2001-03-15 Medicaments permettant de traiter les complications du diabete et des neuropathies et utilisation de ces medicaments

Publications (1)

Publication Number Publication Date
PL357719A1 true PL357719A1 (en) 2004-07-26

Family

ID=18594265

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01357719A PL357719A1 (en) 2000-03-17 2001-03-15 Drugs for complications of diabetes and neuropathy and utilization thereof

Country Status (20)

Country Link
US (1) US20030073729A1 (fr)
EP (1) EP1283054A4 (fr)
KR (2) KR100873585B1 (fr)
CN (2) CN1234414C (fr)
AU (2) AU4116801A (fr)
BR (1) BR0109336A (fr)
CA (1) CA2403442A1 (fr)
CZ (1) CZ20023121A3 (fr)
HK (1) HK1055674A1 (fr)
HU (1) HUP0300325A3 (fr)
IL (1) IL151690A0 (fr)
MX (1) MXPA02009130A (fr)
NO (1) NO20024429L (fr)
NZ (1) NZ521366A (fr)
PL (1) PL357719A1 (fr)
RU (1) RU2281764C2 (fr)
SK (1) SK14922002A3 (fr)
TW (1) TWI305726B (fr)
WO (1) WO2001068136A1 (fr)
ZA (1) ZA200207223B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001294265A1 (en) * 2000-10-18 2002-04-29 Ajinomoto Co., Inc. Process for producing nateglinide crystal
CA2425533C (fr) * 2000-10-18 2010-04-20 Ajinomoto Co., Inc. Procede de production d'acylphenylalanines
WO2002040010A1 (fr) * 2000-10-24 2002-05-23 Ajinomoto Co.,Inc. Preparations de medicament contenant du nateglinide
CA2426745C (fr) * 2000-10-24 2009-09-15 Ajinomoto Co., Inc. Procede de production de cristaux de nateglinide a forme b
CA2426263C (fr) * 2000-10-24 2010-05-25 Ajinomoto Co., Inc. Preparation contenant du nateglinide
WO2002051441A1 (fr) * 2000-12-26 2002-07-04 Sankyo Company, Limited Compositions medicinales contenant un diuretique et un agent renforçant la resistance a l'insuline
US20050096367A1 (en) * 2002-05-28 2005-05-05 Yoshiro Kitahara Pharmaceutical composition for suppression of the expression of ATP citrate lyase and use thereof
ATE495740T1 (de) * 2002-05-28 2011-02-15 Ajinomoto Kk Medizinische zusammensetzungen zur hemmung der expression von atp-citrat-lyase und ihre verwendung
US20050267195A1 (en) * 2002-06-28 2005-12-01 Imao Mikoshiba Drug composition for blood sugar control
WO2004002474A1 (fr) * 2002-06-28 2004-01-08 Kissei Pharmaceutical Co., Ltd. Composition medicamenteuse pour la prevention ou l'inhibition de la progression des complications du diabete
EP1602652A1 (fr) * 2003-03-03 2005-12-07 San-Ei Gen F.F.I., Inc. Promoteur d'expression de l'adiponectine
DK1675625T3 (da) * 2003-09-17 2013-05-13 Univ Texas Mekanisme-baseret målrettet pancreatisk beta-celle-afbildning
WO2005049006A1 (fr) * 2003-11-21 2005-06-02 Ajinomoto Co., Inc. Remede contre les diabetes
EP1750862B1 (fr) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Composition pharmaceutique contenant de l'irbesartan
TW200626163A (en) * 2004-09-22 2006-08-01 Kureha Corp Agent for treating or preventing diabetic neuropathy
CN101111266A (zh) * 2005-01-31 2008-01-23 味之素株式会社 含有降血糖药的用于改善或治疗糖耐量异常、临界性糖尿病、胰岛素抵抗性和高胰岛素血症的药物组合物
CN1947794B (zh) * 2005-10-16 2010-09-01 安徽省现代中药研究中心 含有磺酰脲类和苯氧酸类化合物的药物组合物
WO2007056387A2 (fr) * 2005-11-07 2007-05-18 Elixir Pharmaceuticals, Inc. Combinaisons de metformine et de mitiglinide
KR20110071050A (ko) * 2008-04-29 2011-06-28 파넥스트 알츠하이머 질환 및 관련 장애의 치료를 위한 조니사미드 및 아캄프로세이트의 조합 조성물
CA2727147A1 (fr) * 2008-06-17 2009-12-23 Otsuka Chemical Co., Ltd. Peptide glp-1 glycosyle
MY198422A (en) 2009-04-29 2023-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
NZ627238A (en) 2009-04-29 2016-02-26 Amarin Pharmaceuticals Ie Ltd Stable pharmaceutical composition comprising ethyl eicosapentaenoate
MY172372A (en) 2009-06-15 2019-11-21 Amarin Pharmaceuticals Ie Ltd Compositions and methods for lowering triglycerides
RU2758369C2 (ru) 2009-09-23 2021-10-28 Амарин Фармасьютикалз Айрлэнд Лимитед Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина, и способы ее применения
IT1398168B1 (it) * 2010-02-16 2013-02-14 Chiesi Farma Spa Uso di ingredienti attivi in combinazione per il trattamento delle complicanze del diabete.
US20140127289A1 (en) 2010-11-29 2014-05-08 Armarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2809316A1 (fr) * 2012-01-31 2014-12-10 Mahmut Bilgic Combinaison synergique contenant un dérivé de méglitinide et de l'acide lipoïque
US8492426B1 (en) * 2012-07-12 2013-07-23 Anis Ahmad Use of carvedilol for treatment of diabetes mellitus
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
AU2019349563B2 (en) 2018-09-24 2023-06-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
US10357476B1 (en) 2018-10-30 2019-07-23 Anis Ahmad Method for treating coronary artery disease
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES444756A1 (es) * 1975-01-31 1977-08-16 Ciba Geigy Procedimiento para la obtencion de compuestos basicos insa- turados.
JPS5938960B2 (ja) * 1979-10-12 1984-09-20 呉羽化学工業株式会社 アミノ安息香酸エステル誘導体及び該誘導体を含有する医薬
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
JP2764262B2 (ja) * 1987-08-28 1998-06-11 持田製薬株式会社 ヒダントイン誘導体及びそれを有効成分とする医薬組成物
JP2634450B2 (ja) * 1988-11-11 1997-07-23 株式会社サンギ 糖尿病用薬剤
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
CA2146701A1 (fr) * 1994-04-11 1995-10-12 Takashi Fujita Composes heterocycliques a activite anti-diabetique, leur preparation et leur usage
JPH08157462A (ja) * 1994-12-08 1996-06-18 Terumo Corp ジオキソチアゾリジン誘導体及びそれを含有する医薬組成物
IL117208A0 (en) * 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
JPH08245602A (ja) * 1995-03-08 1996-09-24 Terumo Corp ジオキソチアゾリジン誘導体及びそれを有効成分とする医薬組成物
JPH0995445A (ja) * 1995-07-24 1997-04-08 Kanegafuchi Chem Ind Co Ltd 脳神経細胞障害に対する治療薬
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
ATE322260T1 (de) * 1996-11-15 2006-04-15 Ajinomoto Kk Nateglinide zubereitung in tablettenform
PT1011673E (pt) * 1997-06-13 2001-11-30 Novo Nordisk As Nova posologia para a dmni
EP1045898A2 (fr) * 1998-01-12 2000-10-25 Betagene, Inc. Compositions et procedes regulant la secretion de lignees de cellules neuroendocrines
US6100300A (en) * 1998-04-28 2000-08-08 Bristol-Myers Squibb Company Metformin formulations and method for treating intermittent claudication employing same
AR028299A1 (es) * 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
DE60007592T2 (de) * 1999-09-30 2004-09-16 Pfizer Products Inc., Groton Bicyclische Pyrrolylamide als Glycogenphosphorylase-Inhibitoren
EP1218015A2 (fr) * 1999-10-08 2002-07-03 Novartis AG Procede de traitement de troubles du metabolisme
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
NZ531929A (en) * 1999-12-23 2006-01-27 Novartis Ag Use of nateglinide as a hypoglycemic agent for treating impaired glucose metabolism
MXPA02006443A (es) * 1999-12-28 2002-11-29 Ajinomoto Kk Preparaciones orales para diabetes.
AU2001294265A1 (en) * 2000-10-18 2002-04-29 Ajinomoto Co., Inc. Process for producing nateglinide crystal
CA2425533C (fr) * 2000-10-18 2010-04-20 Ajinomoto Co., Inc. Procede de production d'acylphenylalanines
CA2426745C (fr) * 2000-10-24 2009-09-15 Ajinomoto Co., Inc. Procede de production de cristaux de nateglinide a forme b
CA2426263C (fr) * 2000-10-24 2010-05-25 Ajinomoto Co., Inc. Preparation contenant du nateglinide
WO2002040445A1 (fr) * 2000-11-17 2002-05-23 Novo Nordisk A/S Agonistes de glucagon/antagonistes inverses
US6652838B2 (en) * 2001-04-05 2003-11-25 Robert E. Weinstein Method for treating diabetes mellitus
US6830759B2 (en) * 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
CN101111266A (zh) * 2005-01-31 2008-01-23 味之素株式会社 含有降血糖药的用于改善或治疗糖耐量异常、临界性糖尿病、胰岛素抵抗性和高胰岛素血症的药物组合物

Also Published As

Publication number Publication date
BR0109336A (pt) 2003-06-24
EP1283054A1 (fr) 2003-02-12
WO2001068136A1 (fr) 2001-09-20
KR20020081459A (ko) 2002-10-26
KR20070104953A (ko) 2007-10-29
CN1418109A (zh) 2003-05-14
MXPA02009130A (es) 2003-03-12
CN1768735A (zh) 2006-05-10
TWI305726B (en) 2009-02-01
NO20024429D0 (no) 2002-09-16
HUP0300325A3 (en) 2004-08-30
RU2281764C2 (ru) 2006-08-20
HK1055674A1 (en) 2004-01-21
CA2403442A1 (fr) 2002-09-17
AU4116801A (en) 2001-09-24
CZ20023121A3 (cs) 2003-05-14
US20030073729A1 (en) 2003-04-17
CN1234414C (zh) 2006-01-04
EP1283054A4 (fr) 2006-04-12
ZA200207223B (en) 2003-09-09
KR100873585B1 (ko) 2008-12-11
AU2001241168B2 (en) 2005-06-16
SK14922002A3 (sk) 2003-04-01
HUP0300325A2 (hu) 2003-07-28
NZ521366A (en) 2005-07-29
NO20024429L (no) 2002-11-06
IL151690A0 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
AU4116801A (en) Drugs for complications of diabetes and neuropathy and utilization thereof
AU2001241168A1 (en) Drugs for complications of diabetes and neuropathy and utilization thereof
HK1040995A1 (zh) 二氧喹啉化合物及其醫藥用途
HUP0301325A3 (en) Stabilized pharmaceutically effective composition and pharmaceutical composition comprising the same and process for preparation the composition
AU2002213357A1 (en) Variant igg3 rituxan r and therapeutic use thereof
GC0000307A (en) Pyrimidone compounds and pharmaceutical composition containing them
AU2002241538A1 (en) Intrasvascular drug delivery device and use therefor
AU2002303840A1 (en) Metering and packaging of controlled release medication
GB9927332D0 (en) Novel antibody and uses thereof
AU2002257562A1 (en) Deuterated 3-Piperidinopropiophenone and medicaments containing said compounds
AU2002214006A1 (en) Drugs for diabetes
HUP0300334A3 (en) Pharmaceutical preparations and their manufacture
AU2001288061A1 (en) Drug resistance-associated gene and use thereof
AU2001267645A1 (en) Cyclic urea compounds and preparation thereof
AU2001227084A1 (en) N-arylhydrazide compounds and use thereof as drugs
HK1064042A1 (en) Medicines and medicinal kits
AU2002230781A1 (en) Pharmaceutical uses and synthesis of benzobicyclooctanes
AU2001248753A1 (en) Nitrogenous compounds and antiviral drugs containing the same
HUP0300378A3 (en) Oxazolidinone tablet formulation and their preparation
HUP0303353A3 (en) Preventives and remedies for complications of diabetes
HK1033066A2 (en) A diet medicament with its manufacture and application
HUP0203383A3 (en) Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof
AU1053501A (en) Polyazanaphthalene compound and medicinal use thereof
HUP0201478A3 (en) Neuroprotective and retinoprotective ophthalmologic medicines
AU2001262699A1 (en) Biologically active agents and drugs